Summary: In a prespecified subgroup analysis of the STRIDE trial (792 adults with symptomatic peripheral artery disease and type 2 diabetes), once-weekly subcutaneous semaglutide 1.0 mg improved maximum walking distance at 52 weeks, and this benefit was consistent across diabetes duration, BMI, and HbA1c categories (all interaction P values non-significant). The analysis tested consistency of effect, not a new efficacy claim.
PICO Summary
| Element | Detail |
|---|---|
| Population | 792 adults with symptomatic peripheral artery disease and type 2 diabetes (median diabetes duration 12.2 years, HbA1c 7.1%, BMI 28.7 kg/m2); randomized, double-blind, placebo-controlled trial (STRIDE, NCT04560998); multinational. |
| Intervention | Once-weekly subcutaneous semaglutide 1.0 mg. |
| Comparison | Matched placebo (1:1 randomization within the 792-participant trial population). |
| Outcome | Primary outcome was the estimated treatment ratio (ETR) to baseline in maximum walking distance at 52 weeks. Improvement was consistent across subgroups: diabetes duration (ETR 1.15 vs 1.13 for <10 vs ≥10 years, P=0.80), BMI (1.12 vs 1.16 for <30 vs ≥30 kg/m2, P=0.58), and HbA1c (1.13 for both <7% and ≥7%, P=0.99). Pain-free walking distance was also consistent across subgroups (interaction P>0.1 for all). BMI reduction correlated only weakly with walking improvement. No 95% CI, absolute risk reduction, or NNT applies, as this analysis reports treatment-by-subgroup interactions rather than a single pooled effect estimate. |
Expert Commentary
This report is a prespecified subgroup analysis of the STRIDE trial rather than a fresh efficacy study, and it should be read in that light. The headline finding is one of consistency: the walking-distance benefit of once-weekly semaglutide 1.0 mg was preserved across diabetes duration, BMI, and HbA1c strata, with all treatment-by-subgroup interaction P values clearly non-significant. The verdict is favourable but narrow, namely that the effect seen in the parent trial does not appear to depend on baseline glycaemic control or adiposity, which supports a mechanism beyond weight loss. The most important limitation is that subgroup analyses are exploratory and statistically underpowered to detect interactions, so the absence of a significant interaction is reassuring but not proof of uniform effect. The trial was sponsored by the manufacturer, with several authors employed by the company, and that affiliation warrants the usual caution when interpreting magnitude and framing. Can I use this with my patients? Cautiously yes, for the patient already eligible under the parent STRIDE result, namely an adult with symptomatic peripheral artery disease and type 2 diabetes, since this analysis suggests the walking benefit is not confined to those with obesity or poor glycaemic control. Confirmatory hard-outcome and durability data would strengthen the case further.
References
Rasouli N, Guder Arslan E, Catarig AM, Houlind K, Ludvik B, Nordanstig J, et al. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. 2025;48(9):1529-1535. doi:10.2337/dc25-1082